Confronto

Pasireotid vs. Teduglutid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

396091-73-9

197922-42-2

Peso molecolare

1047.21 g/mol

3752.13 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Teduglutid

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Pasireotid	Teduglutid
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?: Pasireotid is classified as "Ricerca (altro)", while Teduglutid is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pasireotid or Teduglutid?: The highest available evidence level is "RCT sull'uomo" for Pasireotid and "RCT sull'uomo" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pasireotid and Teduglutid in Germany and the United States?: Germania: Pasireotid — Su prescrizione, Teduglutid — Su prescrizione. Stati Uniti: Pasireotid — Su prescrizione, Teduglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Pasireotid

Teduglutid

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Pasireotid and Teduglutid?

Pasireotid is classified as "Ricerca (altro)", while Teduglutid is classified as "Ricerca (altro)". Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pasireotid or Teduglutid?

The highest available evidence level is "RCT sull'uomo" for Pasireotid and "RCT sull'uomo" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pasireotid and Teduglutid in Germany and the United States?

Germania: Pasireotid — Su prescrizione, Teduglutid — Su prescrizione. Stati Uniti: Pasireotid — Su prescrizione, Teduglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.